Juzimette

Metformin Hydrochloride and Sitagliptin, the active ingredient in Juzimette, is a biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control blood glucose levels.

GNH USA supplies Juzimette as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assurance processes and regulatory compliance across EU and other markets, and providing reliable logistics for timely delivery to healthcare providers.

Juzimette, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms. - Type 2 diabetes mellitus: improves glycemic control as part of a comprehensive treatment plan. - Combination therapy with other antidiabetic agents: provides additional glucose lowering when metformin alone is insufficient. - Adjunct to diet and exercise: enhances the effect of lifestyle modifications on blood glucose levels.

Juzimette may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Upper respiratory symptoms: nasopharyngitis or cough. - Headache: mild to moderate intensity. - Hypoglycemia (when used with other glucose‑lowering agents): dizziness or sweating.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic acidosis with rapid breathing. - Pancreatitis: abdominal pain with elevated enzymes. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: jaundice or elevated liver enzymes.

When prescribing Juzimette, clinicians should consider several precautionary measures to ensure patient safety. - Renal function: assess creatinine clearance before initiation and periodically. - Hepatic impairment: avoid in patients with significant liver disease. - Risk of hypoglycemia: monitor when combined with insulin or sulfonylureas. - Lactic acidosis: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: use only if benefits outweigh risks. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Juzimette can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction, increase risk of lactic acidosis. - Cimetidine: can increase metformin plasma levels, raising lactic acidosis risk. - Rifampicin: reduces sitagliptin concentrations, diminishing glucose control.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors/ARBs: monitor renal function and potassium. - Alcohol: enhances risk of lactic acidosis.